Whole blood viscosity measurement in acute myocardial infarction: Feasability and significance;Mesure de la viscosité sanguine au cours de l'infarctus du myocarde aigu reperfusé: Faisabilité et intérêts

Journal des Maladies Vasculaires

Volumn 26, Issue 4, 2001, Pages 243-247

  Philippe, F ^a   Lacombe, C ^a   Bucherer, C ^a   Drobinski, G ^a   Montalescot, G ^a   Thomas, D ^a  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Abciximab; Blood viscosity; Myocardial infarction; Primary angioplasty; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; FIBRINOGEN; FIBRINOLYTIC AGENT; HEPARIN; IONIC CONTRAST MEDIUM; IOXAGLIC ACID;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; BLOOD VISCOSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HEMOSTASIS; HUMAN; PILOT STUDY; SHEAR RATE; VISCOMETER;

ADULT; BLOOD VISCOSITY; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PILOT PROJECTS; THROMBOLYTIC THERAPY;

EID: 0034749197     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Von Willebrand factor, fibrinogen and other plasma proteins as determinants of plasma viscosity
2. Perturbations hémorhéologiques dans le syndrome de menace d'infarctus du myocarde
3. Intérêt et méthodes d'́tude de l'hémorrhéologie en pathologie et pharmacologie vasculaires
4. Glycoprotein IIb/IIIa blockade and thrombolytics: Early lessons from the SPEED and GUSTO IV trials
5. Présentation d'un hémoviscosimètre clinique
6. Relationship between plasma viscosity and the severity of coronary heart disease
7. Lifestyle and hemostatic risk factors for ischemic heart disease: The caerphilly study
8. Recognition of the importance of embolization in atherosclerotic vascular disease
9. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans
10. Pharmacological remodeling of the thrombus architecture
11. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets
12. Direct demonstration of radiolabeled von Willebrand factor binding to platelet glycoprotein Ib and IIb-IIIa in the presence of shear stress
13. Cellular determinants of lowshear blood viscosity
14. Influence des produits de contraste sur l'agrégation et la déformabilite érythrocytaire in vitro
15. Effect of x-ray contrast media on blood flow properties after coronary angiography
16. Influence in vitro de l'albumine, des gammaglobulines et du fibrinogène sur la sédimentation et le comportement rhéologique du globule rouge
17. Analytical model for effects of shear rate on rouleau size and blood viscosity
18. Rheologic modifications induced by heparin therapy. Capillary blood viscosity, erythrocyte deformability, aggregation index
19. Roles of surface electrochemistry and macromolecular adsorption in heparin-induced red blood cell aggregation
20. Heparin effect on red blood cell aggregation
21. Reduced red cell deformability associated with blood flow and platelet activation: Improved by dipyridamole alone or combined with aspirin
22. Erythrocyte aggregation and erythrocyte deformability modify the permeability of erythrocyte enriched fibrin network
23. Intraindividual variability in plasma viscosity in relation to their utility as a cardiovascular risk factor
24. Distribution of blood viscosity values and biochemical correlates in healthy adults